Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald upped their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an overweight rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Down 1.2 %

NASDAQ VNDA opened at $5.02 on Friday. The firm has a market cap of $292.62 million, a P/E ratio of -62.75 and a beta of 0.77. The company’s 50 day moving average is $5.53 and its 200-day moving average is $5.07. Vanda Pharmaceuticals has a 12-month low of $3.30 and a 12-month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. The business had revenue of $50.47 million during the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. Equities analysts expect that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC grew its holdings in shares of Vanda Pharmaceuticals by 57.3% during the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock worth $9,003,000 after purchasing an additional 580,265 shares in the last quarter. Susquehanna Fundamental Investments LLC grew its stake in Vanda Pharmaceuticals by 2.1% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company’s stock worth $1,625,000 after buying an additional 5,994 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 181.7% in the 2nd quarter. AQR Capital Management LLC now owns 75,889 shares of the biopharmaceutical company’s stock worth $429,000 after buying an additional 48,945 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $75,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Vanda Pharmaceuticals by 17.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock valued at $11,379,000 after buying an additional 292,172 shares in the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.